Â鶹´«Ã½¸ßÇå°æ

Anna J Podolanczuk, MD, MS

Pulmonary Critical Care Medicine

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

*Indicates this doctor is no longer accepting new patients with this insurance plan.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

I am a physician-scientist specializing in the care of patients with interstitial lung disease and pulmonary fibrosis. I strive to combine state of the art evidence-based medicine with personalized care for patients with advanced pulmonary diseases. My research program complements my clinical practice and aims to advance our understanding of pulmonary fibrosis in humans. By combining clinical observations with translational research methods, I hope to move us closer to finding a cure for pulmonary fibrosis.

Biographical Info

Dr. Podolanczuk is a nationally and internationally recognized expert in interstitial lung disease. She received her undergraduate degree in Neuroscience from Brown University. She earned her MD from NYU School of Medicine. She completed residency in Internal Medicine and fellowship in Pulmonary and Critical Care Medicine at Columbia University. She received additional training in advanced pulmonary diseases at Columbia University. She also earned a Masters of Science in Patient-Oriented Research from Columbia’s Mailman School of Public Health, with a focus on epidemiology and biostatistics.

Dr. Podolanczuk is an NIH-funded investigator studying novel risk factors for pulmonary fibrosis in humans. Her research program focuses on understanding early or subclinical interstitial lung disease, characterizing imaging and blood biomarkers of pulmonary fibrosis, the role of environmental exposures, and the connection between cardiovascular disease and pulmonary fibrosis. She is also a site investigator for several multi-center clinical trials of new therapies for pulmonary fibrosis.

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine (Critical Care Medicine)
American Board of Internal Medicine (Pulmonary Disease)
Clinical Expertise
Interstitial Lung Disease
Pulmonary Fibrosis
Languages
English
Polish
Spanish
Research
Education 
  • M.S.
    Columbia University
    2017
  • M.D.
    New York University School of Medicine
    2008
  • B.S.
    Brown University
    2002
Appointments 
  • Assistant Attending Physician
    NewYork-Presbyterian Hospital
  • Assistant Professor of Medicine
    Weill Cornell Medical College, Cornell University
  • Helen and Robert Appel Clinical Scholar
    Weill Cornell Medical College, Cornell University

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Consultant: 
Boehringer Ingelheim Pharmaceuticals, Inc. (USA)
EBSCO
Eisai, Inc.
Imvaria Inc.
Pliant Therapeutics, Inc
Regeneron Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc.
Veracyte, Inc.
Advisory/Scientific Board Member: 
Boehringer Ingelheim Pharmaceuticals, Inc. (USA)
PureTech Health
United Therapeutics
Other Interest: 
Trevi Therapeutics